Schizadrin B Detection in Blood Plasma via UPLC-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lack of pharmacokinetics research on strengthening body resistance and dissipating blood stasis botanicals hinders quality control and clinical administration, particularly due to the absence of detection methods for schizadrin B in blood plasma.
Innovation Solution
A detection method involving ethyl acetate extraction and UPLC/MS analysis is used to extract and quantify schizadrin B in mammalian plasma, employing a specific chromatographic column and mass spectrometric conditions to enhance resolution and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional extraction and detection methods are used, then the detection process is simple, but the resolution and sensitivity are insufficient to detect schizadrin B in blood plasma
Solution Approach 1:
The patent combines UPLC (ultra-performance liquid chromatography) and MS (mass spectrometry) into a hybrid UPLC-MS system. This merging of two analytical techniques allows the detection method to achieve both high resolution separation of schizadrin B from other plasma components and high sensitivity detection, resolving the contradiction between detection sensitivity and system complexity by integrating functions rather than using separate systems.
Solution Approach 2:
The patent employs specific parameter optimizations including mobile phase composition (acetonitrile-water-formic acid ratios), gradient elution programs, ion source temperature (100°C), desolvation gas flow (440 L/h), and cone voltage settings. These parameter changes enable the UPLC-MS system to achieve optimal resolution and sensitivity for schizadrin B detection, transforming the detection capability through precise parameter control.
2Quantity of substance
If liquid-liquid extraction is used to extract schizadrin B from plasma, then the extraction efficiency is improved, but the analysis time increases
Solution Approach 1:
The patent performs preliminary liquid-liquid extraction of plasma samples with ethyl acetate before UPLC-MS analysis. This preliminary action pre-concentrates schizadrin B from the plasma matrix, improving extraction efficiency and reducing matrix interference. By performing this extraction step beforehand, the subsequent UPLC analysis can be optimized for faster elution, thus reducing overall analysis time while maintaining high extraction efficiency.
Solution Approach 2:
The patent extracts schizadrin B from the complex plasma matrix into ethyl acetate organic phase. This extraction separates the target compound from interfering plasma components, concentrating schizadrin B into a smaller volume of organic solvent. This taking out of the target compound from the complex matrix improves both extraction efficiency and subsequent detection speed by reducing sample preparation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the detection of schizadrin B in blood plasma, facilitating pharmacokinetic research and improving the understanding of its plasma concentration, thereby supporting quality control and clinical administration.
Implementation Method 1
Mammal plasma containing drugs after being administered the strengthening body resistance and dissipating blood stasis botanical was extracted with ethyl acetate at the volume ratio of 1:4
Implementation Method 2
a UPLC system is used to separate analyte with other components
Implementation Method 3
MS condition: electrospray ionization (ESI) ion source, detection with positive ion mode, scanning at the range of m/z 150 to 1200
Implementation Method 4
whirling for 3 to 5 min, then centrifuging at 9600 rpm for 10 min
Data Source
AI summary
A detection method of blood plasma schizadrin B of dissipating blood stasis botanical is disclosed. The method includes: (1) extracting schizadrin B from plasma of mammalian administered dissipating blood stasis botanical by ethyl acetate with the volume ratio 1:4, whirling 3-5 mins, centrifugating at 9600 rpm for 10 mins, drying and enriching the upper layer at 25-30° C., and redissolving with mobile phase; (2) UPLC/MS measuring: UPLC condition: chromatographic column: Acquity UPLC BEH C18, 2.1′100 mm, mobile phase A: water-acetonitrile-formic acid 95:5:0.1 v/v/v, mobile phase B: acetonitrile-formic acid 100:0.1 v/v; MS condition: electric spraying ion source (ESI), detecting with positive ion mode, scanning at the range of m/z 150-1200. The method can be used for pharmacokinetics study of schizadrin B in dissipating blood stasis botanical.